Early prostate-specific antigen (Psa) change at four weeks of the first-line treatment using abiraterone and enzalutamide could predict early/primary resistance in metastatic castration-resistant prostate cancer

Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Naokazu Ibuki, Hajime Hirano, Hayahito Nomi, Kiyoshi TakaharaTeruo Inamoto, Shin Egawa, Haruhito Azuma

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Early prostate-specific antigen (Psa) change at four weeks of the first-line treatment using abiraterone and enzalutamide could predict early/primary resistance in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences